Catalyst Event
Sino Biopharmaceutical Ltd (1177) · Other
From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)
5/28/2026, 12:00:00 AM
The company's subsidiary, Chia Tai Tianqing, announced that its innovative IDH1 inhibitor, TQB3454, was granted priority review by China's Center for Drug Evaluation (CDE) for the treatment of advanced biliary tract cancer on 2026-05-28. This is estimated to have a medium market impact of approximately 5% due to the potential for accelerated market entry.
Korean Translation
자회사 정대천청의 혁신적 IDH1 억제제 TQB3454가 2026-05-28 중국 국가약품감독관리국 약품심사평가센터(CDE)로부터 진행성 담도암 치료 우선심사 대상으로 지정됨. 신속한 시장 진입 가능성으로 약 5%의 시장 영향이 예상됨.
Related Recent Events
Eli Lilly and Co (LLY) · Earnings Release
Q2 2026 earnings release and conference call. Medium importance is estimated as earnings releases typically cause >5% price volatility scheduled.
8/5/2026, 12:00:00 AM
Boston Scientific Corp (BSX) · Earnings Release
The Q2 2026 earnings release scheduled for 2026-07-29, for which high importance is estimated due to typical market volatility surrounding quarterly results, is expected.
7/29/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Q2 2026 earnings release is scheduled for July 16, 2026; a price impact of at least 5% is estimated based on historical volatility, scheduled.
7/16/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Final dividend of HKD 0.20 per share ex-dividend on July 3, 2026; standard corporate action with minor price adjustment scheduled.
7/3/2026, 12:00:00 AM
CSPC Pharmaceutical Group Ltd (1093) · Other
Ex-dividend date for the 2025 final dividend of HK$0.15 per share, which was announced on March 25, 2026. The payment date is July 15, 2026.
6/24/2026, 12:00:00 AM
Sonova Holding AG (SOON) · Other
Ex-dividend date (2026-06-19) for a proposed record-high annual dividend of CHF 4.70 per share; impact estimated at ~2% as dividend is record-high, scheduled.
6/19/2026, 12:00:00 AM